198 related articles for article (PubMed ID: 6487375)
1. Modulation of anti-metabolite effects. Effects of thymidine on the efficacy of the quinazoline-based thymidylate synthetase inhibitor, CB3717.
Jackman AL; Taylor GA; Calvert AH; Harrap KR
Biochem Pharmacol; 1984 Oct; 33(20):3269-75. PubMed ID: 6487375
[TBL] [Abstract][Full Text] [Related]
2. Biochemical effects of a quinazoline inhibitor of thymidylate synthetase, N-(4-(N-(( 2-amino-4-hydroxy-6-quinazolinyl)methyl)prop-2-ynylamino) benzoyl)-L-glutamic acid (CB3717), on human lymphoblastoid cells.
Jackson RC; Jackman AL; Calvert AH
Biochem Pharmacol; 1983 Dec; 32(24):3783-90. PubMed ID: 6661252
[TBL] [Abstract][Full Text] [Related]
3. Activity of the thymidylate synthase inhibitor 2-desamino-N10-propargyl-5,8-dideazafolic acid and related compounds in murine (L1210) and human (W1L2) systems in vitro and in L1210 in vivo.
Jackman AL; Taylor GA; O'Connor BM; Bishop JA; Moran RG; Calvert AH
Cancer Res; 1990 Sep; 50(17):5212-8. PubMed ID: 2386929
[TBL] [Abstract][Full Text] [Related]
4. The biochemical pharmacology of the thymidylate synthase inhibitor, 2-desamino-2-methyl-N10-propargyl-5,8-dideazafolic acid (ICI 198583).
Jackman AL; Newell DR; Gibson W; Jodrell DI; Taylor GA; Bishop JA; Hughes LR; Calvert AH
Biochem Pharmacol; 1991 Oct; 42(10):1885-95. PubMed ID: 1741766
[TBL] [Abstract][Full Text] [Related]
5. Increased thymidylate synthase in L1210 cells possessing acquired resistance to N10-propargyl-5,8-dideazafolic acid (CB3717): development, characterization, and cross-resistance studies.
Jackman AL; Alison DL; Calvert AH; Harrap KR
Cancer Res; 1986 Jun; 46(6):2810-5. PubMed ID: 2938731
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB3717) in the mouse.
Newell DR; Alison DL; Calvert AH; Harrap KR; Jarman M; Jones TR; Manteuffel-Cymborowska M; O'Connor P
Cancer Treat Rep; 1986 Aug; 70(8):971-9. PubMed ID: 3731153
[TBL] [Abstract][Full Text] [Related]
7. Thymidylate synthase: a target for anticancer drug design.
Harrap KR; Jackman AL; Newell DR; Taylor GA; Hughes LR; Calvert AH
Adv Enzyme Regul; 1989; 29():161-79. PubMed ID: 2633608
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of cell death following thymidylate synthase inhibition: 2'-deoxyuridine-5'-triphosphate accumulation, DNA damage, and growth inhibition following exposure to CB3717 and dipyridamole.
Curtin NJ; Harris AL; Aherne GW
Cancer Res; 1991 May; 51(9):2346-52. PubMed ID: 2015598
[TBL] [Abstract][Full Text] [Related]
9. Potentiation of quinazoline antifolate (CB3717) toxicity by dipyridamole in human lung carcinoma, A549, cells.
Curtin NJ; Harris AL
Biochem Pharmacol; 1988 Jun; 37(11):2113-20. PubMed ID: 3377815
[TBL] [Abstract][Full Text] [Related]
10. Formation and retention and biological activity of N10-propargyl-5,8-dideazafolic acid (CB3717) polyglutamates in L1210 cells in vitro.
Sikora E; Jackman AL; Newell DR; Calvert AH
Biochem Pharmacol; 1988 Nov; 37(21):4047-54. PubMed ID: 2461200
[TBL] [Abstract][Full Text] [Related]
11. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study.
Jackman AL; Taylor GA; Gibson W; Kimbell R; Brown M; Calvert AH; Judson IR; Hughes LR
Cancer Res; 1991 Oct; 51(20):5579-86. PubMed ID: 1913676
[TBL] [Abstract][Full Text] [Related]
12. Potentiation of the cytotoxicity of thymidylate synthase (TS) inhibitors by dipyridamole analogues with reduced alpha1-acid glycoprotein binding.
Curtin NJ; Bowman KJ; Turner RN; Huang B; Loughlin PJ; Calvert AH; Golding BT; Griffin RJ; Newell DR
Br J Cancer; 1999 Aug; 80(11):1738-46. PubMed ID: 10468290
[TBL] [Abstract][Full Text] [Related]
13. Thymidine phosphorylase moderates thymidine-dependent rescue after exposure to the thymidylate synthase inhibitor ZD1694 (Tomudex) in vitro.
Patterson AV; Talbot DC; Stratford IJ; Harris AL
Cancer Res; 1998 Jul; 58(13):2737-40. PubMed ID: 9661884
[TBL] [Abstract][Full Text] [Related]
14. Thymidylate synthetase-deficient mouse FM3A mammary carcinoma cell line as a tool for studying the thymidine salvage pathway and the incorporation of thymidine analogues into host cell DNA.
Balzarini J; De Clercq E; Ayusawa D; Seno T
Biochem J; 1984 Jan; 217(1):245-52. PubMed ID: 6696722
[TBL] [Abstract][Full Text] [Related]
15. Thymidylate synthetase-positive and -negative murine mammary FM3A carcinoma cells as a useful system for detecting thymidylate synthetase inhibitors.
Balzarini J; de Clercq E; Ayusawa D; Seno T
FEBS Lett; 1984 Jul; 173(1):227-32. PubMed ID: 6745430
[TBL] [Abstract][Full Text] [Related]
16. Quinazoline antifolate thymidylate synthase inhibitors: replacement of glutamic acid in the C2-methyl series.
Marsham PR; Jackman AL; Barker AJ; Boyle FT; Pegg SJ; Wardleworth JM; Kimbell R; O'Connor BM; Calvert AH; Hughes LR
J Med Chem; 1995 Mar; 38(6):994-1004. PubMed ID: 7699716
[TBL] [Abstract][Full Text] [Related]
17. A potent antitumour quinazoline inhibitor of thymidylate synthetase: synthesis, biological properties and therapeutic results in mice.
Jones TR; Calvert AH; Jackman AL; Brown SJ; Jones M; Harrap KR
Eur J Cancer (1965); 1981 Jan; 17(1):11-9. PubMed ID: 7262141
[No Abstract] [Full Text] [Related]
18. Role of thymidylate synthetase activity in development of methotrexate cytotoxicity.
Moran RG; Mulkins M; Heidelberger C
Proc Natl Acad Sci U S A; 1979 Nov; 76(11):5924-8. PubMed ID: 160558
[TBL] [Abstract][Full Text] [Related]
19. Comparison of in vitro and in vivo effects of thymidine on L1210 leukemia in mice.
Zaharko DS; Ramonas LM
J Natl Cancer Inst; 1982 May; 68(5):875-80. PubMed ID: 6951095
[TBL] [Abstract][Full Text] [Related]
20. Quinoline antifolate thymidylate synthase inhibitors: variation of the C2- and C4-substituents.
Warner P; Barker AJ; Jackman AL; Burrows KD; Roberts N; Bishop JA; O'Connor BM; Hughes LR
J Med Chem; 1992 Jul; 35(15):2761-8. PubMed ID: 1495009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
